Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0P7KI
|
|||
| Former ID |
DIB010292
|
|||
| Drug Name |
Anti-CD3 and anti-Her2/neu bispecific antibody-armed activated T cells
|
|||
| Synonyms |
Her2Bi-armed activated T cells (breast cancer), Barbara Ann Karmanos Cancer Institute; Anti-CD3 and anti-Her2/neu bispecific antibody-armed activated T cells (breast cancer); Anti-CD3 and anti-Her2/neu bispecific antibody-armed activated T cells (breast cancer), Barbara Ann Karmanos Cancer Institute
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Breast cancer [ICD-11: 2C60-2C65] | Phase 2 | [1] | |
| Company |
Transtarget; barbara ann karmanos cancer institute
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Journal of Clinical Oncology, 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition), Vol 26, No 15S (May 20 Supplement), 2008: 3034. | |||
| REF 2 | Use of anti-CD3 x anti-HER2/neu bispecific antibody for redirecting cytotoxicity of activated T cells toward HER2/neu+ tumors. J Hematother Stem Cell Res. 2001 Apr;10(2):247-60. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.